Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana.
In a randomized controlled trial in a measles endemic area, standard-dose (4.0 log10pfu) AIK-C measles vaccine administered at 6 months of age was compared to standard-dose Schwarz vaccine (3.7log10pfu) given at 9 months. Seroconversion rates at 3 and 6 months after immunization in the two groups were comparable and similar. The geometric mean titres achieved were, however, significantly higher in the Schwarz group (P < 0.05). No immediate serious side-effects were observed with either vaccine. We conclude that standard-dose AIK-C measles vaccine can be recommended for measles immunization in children below 9 months of age, especially in highly endemic and high-risk areas in developing countries.
Nkrumah
F K
FK
Noguchi Memorial Institute for Medical Research (NMIMR), University of Ghana, Legon, Ghana.
Osei-Kwasi
M
M
Dunyo
S K
SK
Koram
K A
KA
Afari
E A
EA
D000367:Age Factors; D000914:Antibodies, Viral / Q000032:analysis; D003627:Data Interpretation, Statistical; D019353:Endemic Diseases; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D005869:Ghana; D006801:Humans; D007223:Infant; D008297:Male; D008457:Measles / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D008459:Measles virus / Q000276:immunology; D013997:Time Factors
D000914:Antibodies, Viral; D008458:Measles Vaccine